Lista de obras -

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS ⬇️

artículo científico publicado el 16 de febrero de 2011

A patient with Fechtner syndrome successfully treated with romiplostim ⬇️

artículo científico publicado el 25 de enero de 2012

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

artículo científico publicado en 2011

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

artículo científico publicado en 2017

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

artículo científico publicado en 2016

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

artículo científico publicado en 2015

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

artículo científico publicado en 2010

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

artículo científico publicado en 2006

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).

artículo científico publicado en 2015

Causes of death in 2877 patients with myelodysplastic syndromes

artículo científico publicado en 2016

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years

artículo científico publicado en 2015

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

artículo científico publicado en 2017

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System ⬇️

artículo científico publicado el 25 de abril de 2011

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

artículo científico publicado en 2015

Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report.

artículo científico publicado en 2018

Current treatment algorithm for the management of lower-risk MDS.

artículo científico publicado en 2017

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide ⬇️

artículo científico publicado el 25 de noviembre de 2010

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy

artículo científico publicado en 2010

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro

artículo científico publicado en 2015

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes a

Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

artículo científico publicado en 2014

Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH

artículo científico publicado en 2010

Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care ⬇️

artículo científico publicado el 5 de mayo de 2012

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group

artículo científico publicado en 2015

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

artículo científico publicado en 2006

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes

artículo científico publicado en 2008

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider

artículo científico publicado en 2014

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

article

Impact on survival of different treatments for myelodysplastic syndromes (MDS).

artículo científico publicado en 2009

Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes

artículo científico publicado en 2016

Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature

artículo científico publicado en 2017

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

artículo científico publicado en 2014

Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes ⬇️

artículo científico publicado el 1 de octubre de 2012

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses

artículo científico publicado en 2006

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

artículo científico publicado en 2007

Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias

artículo científico

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial

artículo científico publicado en 2018

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

artículo científico publicado en 2013

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

artículo científico publicado en 2011

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

artículo científico publicado en 2017

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes

artículo científico publicado en 2009

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study

artículo científico publicado en 2013

Morphology, cytogenetics and classification of MDS.

artículo científico publicado en 2013

Myelodysplastic syndromes. Diagnosis and therapeutic strategies

artículo científico publicado en 2002

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge ⬇️

artículo científico publicado el 13 de febrero de 2012

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

artículo científico publicado en 2017

Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling

artículo científico publicado en 2005

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

artículo científico publicado en 2014

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

artículo científico publicado en 2012

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

artículo científico publicado en 2009

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

artículo científico publicado en 2017

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

artículo científico publicado en 2008

Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.

artículo científico publicado en 2004

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

artículo científico publicado en 2017

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes

artículo científico publicado en 2006

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

artículo científico publicado en 2016

Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil.

artículo científico publicado en 2009

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

artículo científico publicado en 2006

Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals

artículo científico publicado en 2003

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

artículo científico publicado en 2014

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

artículo científico publicado en 2012

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial

artículo científico publicado en 2015

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease

artículo científico publicado en 2007

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

artículo científico publicado en 2013

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

artículo científico publicado en 2013

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes

artículo científico publicado en 2013

The 5q- syndrome.

artículo científico publicado en 2008

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

artículo científico publicado en 2017

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

artículo científico publicado en 2018

The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome

artículo científico publicado en 2005

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts

artículo científico publicado en 2008

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

artículo científico publicado en 2016

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study

artículo científico publicado en 2005

Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia

artículo científico publicado en 2012

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts

artículo científico publicado en 2012

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group

artículo científico publicado en 2014

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

artículo científico publicado en 2013

Where Does Lenalidomide Fit in Non-del(5q) MDS?

artículo científico

X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns

artículo científico publicado en 2006

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

artículo científico publicado en 2014

Eficacia de la azacitidina en comparación con los regímenes de atención convencionales en el tratamiento de los síndromes mielodisplásicos de mayor riesgo: un estudio de fase III, aleatorizado, abierto

artículo científico publicado en 2009

Lista de obras de

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS ⬇️

A patient with Fechtner syndrome successfully treated with romiplostim ⬇️

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).

Causes of death in 2877 patients with myelodysplastic syndromes

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System ⬇️

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report.

Current treatment algorithm for the management of lower-risk MDS.

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide ⬇️

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes a

Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH

Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care ⬇️

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Impact on survival of different treatments for myelodysplastic syndromes (MDS).

Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes

Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes ⬇️

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study

Morphology, cytogenetics and classification of MDS.

Myelodysplastic syndromes. Diagnosis and therapeutic strategies

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge ⬇️

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil.

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes

The 5q- syndrome.

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study

Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

Where Does Lenalidomide Fit in Non-del(5q) MDS?